Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

Written by David Shapiro | Oct 1, 2026, 1:00:00 PM

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

Published 2:50 PM CDT, October 1, 2026

SARASOTA, FL -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.

Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1

Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City. He will also attend and present at the ThinkEquity Conference on October 15, 2026, in New York City. Later in the month, Dr. Cooper will present a poster on Nu-3 preclinical data at IDWeek on October 22, 2026, in Washington D.C.

Details are as follows:

Event: Maxim Growth Summit

Date: October 13-14, 2026

Location: Hard Rock Hotel, New York City

Event: ThinkEquity Conference

Date: October 15, 2026

Location: The Mandarin Oriental Hotel, New York City

Presentation: Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers

Presentation Time: 3:30 pm

Event: IDWeek

Date: October 21-24, 2026

Location: Walter E. Washington Convention Center, Washington, D.C. (Hybrid Format Available)

The conferences provide opportunities for Lakewood-Amedex to engage with members of the investment, biotechnology, and infectious disease communities and highlight the Company’s ongoing development programs Bisphosphocin® antimicrobial technology.

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ:LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.